IDO mRNA is highly expressed in ≥90% of GBM patients presenting with wild-type isocitrate dehydrogenase (wtIDH) and while not normally expressed, is inducible among a majority of human GBM cell lines after exposure to proinflammatory cytokines (23, 66, 107–110). The gene discussed is IDH3A; the disease is glioblastoma.